A Luana Stanescu1, Dennis W Shaw2, Nozomu Murata3,4, Kiyoko Murata3,5, Joe C Rutledge6, Ezekiel Maloney2, Kenneth R Maravilla3. 1. Department of Radiology, Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, M/S MA 7.220, Seattle, WA, 98105, USA. stanescu@u.washington.edu. 2. Department of Radiology, Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, M/S MA 7.220, Seattle, WA, 98105, USA. 3. Department of Radiology, University of Washington, Seattle, WA, USA. 4. Department of Radiology, Toho University Ohashi Medical Center, Tokyo, Japan. 5. Department of Neurology, Toho University Omori Medical Center, Tokyo, Japan. 6. Department of Pathology, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Retained gadolinium from gadolinium-based contrast agents (GBCAs) used in MR exams has been inferred based on signal changes on serial brain MRI and subsequently demonstrated pathologically in adults. Retention has been similarly inferred in children but pathological demonstration in pediatric patients is limited. The long-term effects of retained gadolinium are unknown but are potentially of greater concern in children given their increased vulnerability from continuing development and their expected longer period of exposure. Several factors can influence gadolinium retention. In adults as well as in children, greater accumulation has been demonstrated based on MR signal changes with linear compared with macrocyclic gadolinium chelates, attributed to lower chelate affinity with linear agents. Effects of age at exposure on retention are unknown, while differences in GBCA washout rates are still under investigation and might affect gadolinium retention relative to time of GBCA administration. OBJECTIVE: The purpose of this study was to confirm whether gadolinium brain deposits are present in pediatric patients who received GBCAs and to quantify the amounts present. MATERIALS AND METHODS: Brain autopsy specimens from 10 pediatric patients between 1 year and 13 years of age who underwent at least one contrast-enhanced MR exam were analyzed for elemental gadolinium using inductively coupled plasma mass spectrometry. Brain samples included white matter, basal ganglia (putamen, globus pallidus), thalamus, dentate nucleus and tumor tissue as available. Type and dose of contrast agent, number and timing of contrast-enhanced MR exams and renal function (estimated glomerular filtration rate [eGFR]) were documented for each child. RESULTS: Patient exposures ranged from 1 dose to 20 doses of GBCAs including both macrocyclic and linear ionic agents. Gadolinium was found to be present in brain tissue in all children and was generally highest in the globus pallidus. Those who received only macrocyclic agents showed lower levels of gadolinium retention. CONCLUSION: This study demonstrates pathological confirmation of gadolinium retention in brain tissue of a series of pediatric patients exposed to GBCAs including not only linear ionic agents but also macrocyclic agents with both nonionic and ionic compounds. The distribution and deposition levels in this small pediatric population are comparable with the findings in adults. While the clinical significance of these deposits remains unknown, at this point it would be prudent to exert caution and avoid unnecessary use of GBCAs in pediatric patients.
BACKGROUND: Retained gadolinium from gadolinium-based contrast agents (GBCAs) used in MR exams has been inferred based on signal changes on serial brain MRI and subsequently demonstrated pathologically in adults. Retention has been similarly inferred in children but pathological demonstration in pediatric patients is limited. The long-term effects of retained gadolinium are unknown but are potentially of greater concern in children given their increased vulnerability from continuing development and their expected longer period of exposure. Several factors can influence gadolinium retention. In adults as well as in children, greater accumulation has been demonstrated based on MR signal changes with linear compared with macrocyclic gadolinium chelates, attributed to lower chelate affinity with linear agents. Effects of age at exposure on retention are unknown, while differences in GBCA washout rates are still under investigation and might affect gadolinium retention relative to time of GBCA administration. OBJECTIVE: The purpose of this study was to confirm whether gadolinium brain deposits are present in pediatric patients who received GBCAs and to quantify the amounts present. MATERIALS AND METHODS: Brain autopsy specimens from 10 pediatric patients between 1 year and 13 years of age who underwent at least one contrast-enhanced MR exam were analyzed for elemental gadolinium using inductively coupled plasma mass spectrometry. Brain samples included white matter, basal ganglia (putamen, globus pallidus), thalamus, dentate nucleus and tumor tissue as available. Type and dose of contrast agent, number and timing of contrast-enhanced MR exams and renal function (estimated glomerular filtration rate [eGFR]) were documented for each child. RESULTS:Patient exposures ranged from 1 dose to 20 doses of GBCAs including both macrocyclic and linear ionic agents. Gadolinium was found to be present in brain tissue in all children and was generally highest in the globus pallidus. Those who received only macrocyclic agents showed lower levels of gadolinium retention. CONCLUSION: This study demonstrates pathological confirmation of gadolinium retention in brain tissue of a series of pediatric patients exposed to GBCAs including not only linear ionic agents but also macrocyclic agents with both nonionic and ionic compounds. The distribution and deposition levels in this small pediatric population are comparable with the findings in adults. While the clinical significance of these deposits remains unknown, at this point it would be prudent to exert caution and avoid unnecessary use of GBCAs in pediatric patients.
Authors: Alexander Radbruch; Robert Haase; Philipp Kickingereder; Philipp Bäumer; Sebastian Bickelhaupt; Daniel Paech; Wolfgang Wick; Heinz-Peter Schlemmer; Angelika Seitz; Martin Bendszus Journal: Radiology Date: 2017-03-08 Impact factor: 11.105
Authors: Maria Camilla Rossi Espagnet; Bruno Bernardi; Luca Pasquini; Lorenzo Figà-Talamanca; Paolo Tomà; Antonio Napolitano Journal: Pediatr Radiol Date: 2017-09
Authors: Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen Journal: J Am Soc Nephrol Date: 2006-08-02 Impact factor: 10.121
Authors: D R Roberts; A R Chatterjee; M Yazdani; B Marebwa; T Brown; H Collins; G Bolles; J M Jenrette; P J Nietert; X Zhu Journal: AJNR Am J Neuroradiol Date: 2016-07-28 Impact factor: 3.825
Authors: Martin A Sieber; Philipp Lengsfeld; Jakob Walter; Heiko Schirmer; Thomas Frenzel; Fred Siegmund; Hanns-Joachim Weinmann; Hubertus Pietsch Journal: J Magn Reson Imaging Date: 2008-05 Impact factor: 4.813
Authors: Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch Journal: Eur Radiol Date: 2008-06-11 Impact factor: 5.315
Authors: Skorn Ponrartana; Michael M Moore; Sherwin S Chan; Teresa Victoria; Jonathan R Dillman; Govind B Chavhan Journal: Pediatr Radiol Date: 2021-04-19
Authors: Zheng Han; Chuheng Chen; Xiang Xu; Renyuan Bai; Verena Staedtke; Jianpan Huang; Kannie W Y Chan; Jiadi Xu; David O Kamson; Zhibo Wen; Linda Knutsson; Peter C M van Zijl; Guanshu Liu Journal: NMR Biomed Date: 2021-11-15 Impact factor: 4.044
Authors: Holden T Maecker; Janet C Siebert; Yael Rosenberg-Hasson; Lorrin M Koran; Miguel Ramalho; Richard C Semelka Journal: Invest Radiol Date: 2022-01-01 Impact factor: 6.016
Authors: Haifa Al-Sarhani; Ravi V Gottumukkala; Angelo Don S Grasparil; Eric L Tung; Michael S Gee; Mary-Louise C Greer Journal: Pediatr Radiol Date: 2021-04-01